7/8/2026
Chemomab and Scipher Merge to Bring AI-Guided Precision Medicine to Rheumatoid Arthritis
Two small-cap biotechs are betting that artificial intelligence can succeed where a decade of drug development has stalled. Chemomab Therapeutics (Nasdaq: CMMB) and Scipher Medicine announced this morning that they have entered into a definitive merger agreement, combining Chemomab’s clinical-stage antibody nebokitug with Scipher’s AI-powered precision medicine platform to attack rheumatoid arthritis from a completely different angle than anything currently on the market.
0
3 min read